Letrozole-d4

Letrozole-d4 (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].

Product Specifications

CAS Number

[1133712-96-5]

UNSPSC

12352005

Hazard Statement

H351, H360, H373

Target

Autophagy; Cytochrome P450; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.23

Solubility

10 mM in DMSO|DMF : ≥ 16mg/mL|DMSO : ≥ 16mg/mL

Smiles

C(C1=C(C(=C(C#N)C(=C1[2H])[2H])[2H])[2H])(C2=CC=C(C#N)C=C2)N3C=NC=N3

Molecular Formula

C17H7D4N5

Molecular Weight

289.33

Precautions

H351, H360, H373

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37 (6) :1021-7.|[3]Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104 (2) :155-60.|[4]Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44 (4-6) :633-6.